| Name | Title | Contact Details |
|---|---|---|
Ashwin Altekar |
Vice President of Information Security | Profile |
R&D Medical Products is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Goldfish Swim School was founded in 2005 by husband and wife team Chris and Jenny McCuiston. Chris and Jenny took a concept that they formulated with nearly two years of research, and cultivated a business that provides results in the learn-to-swim environment that you simply can`t find anywhere else. Their proprietary curriculum and systems were developed after traveling the country in search of the “best practices” to teach babies and young children how to swim. The first school, in Birmingham, Michigan, opened in 2006, and quickly saw success. Opening its doors with over 500 students at inception, Goldfish currently teaches more than 70,000 students per month across the franchise system. At the beginning of 2008, it made sense to begin the franchising process. As of early 2017, we are currently in the process of expanding franchise opportunities throughout the country and internationally, with over 80 schools open or in development in more than 23 states and Canada.
Mauna Kea Technologies is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
MBI Solutions is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.